These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33183981)

  • 1. Effectiveness of omalizumab in two cases of normocomplementemic urticarial vasculitis due to perivascular mast cell infiltration.
    Ito T; Maeda T; Egusa C; Abe N; Seshimo H; Okubo Y; Harada K
    Allergol Int; 2021 Apr; 70(2):269-270. PubMed ID: 33183981
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome.
    Aurich S; Simon JC; Treudler R
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e395-e397. PubMed ID: 28273376
    [No Abstract]   [Full Text] [Related]  

  • 3. A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab.
    Nucera E; Basta F; Buonomo A; Mezzacappa S; Margiotta DP; Antonelli Incalzi R; Schiavino D
    J Investig Allergol Clin Immunol; 2017; 27(6):382-384. PubMed ID: 29199964
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.
    Rattananukrom T; Svetvilas P; Chanprapaph K
    Asian Pac J Allergy Immunol; 2020 Dec; 38(4):286-289. PubMed ID: 30660172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
    Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
    Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.
    Cherrez-Ojeda I; Vanegas E; Felix M; Mata VL; Cherrez A
    BMC Dermatol; 2018 Oct; 18(1):8. PubMed ID: 30359231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Hypocomplementemic Urticarial Vasculitis With Omalizumab: A Case Report.
    Pérez Codesido S; Rosado Ingelmo A; Gómez de la Fuente E; García García E; Privitera Torres M; Tejedor Alonso MA
    J Investig Allergol Clin Immunol; 2020 Jun; 30(3):211-212. PubMed ID: 32571766
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.
    Kai AC; Flohr C; Grattan CE
    Clin Exp Dermatol; 2014 Jul; 39(5):651-2. PubMed ID: 24758481
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-Term Efficacy and Safety of Omalizumab Monotherapy in a Patient With Normocomplementemic Urticarial Vasculitis.
    Abuzakouk M; Ghorab O; Namas R; Maurer M
    J Drugs Dermatol; 2022 Oct; 21(10):1124-1126. PubMed ID: 36219045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the effects of omalizumab in refractory chronic spontaneous urticaria?
    López M; Navajas-Galimany L
    Medwave; 2015 Dec; 15 Suppl 3():e6346. PubMed ID: 26731420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of omalizumab in severe solar urticaria.
    de Dios-Velázquez Á; González-de Arriba M; Beteta-Gorriti V; Macías E; Campanón-Toro V; Dávila I
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):260-2. PubMed ID: 26803538
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy.
    Ensina LF; Cusato-Ensina AP; Camelo-Nunes IC; Solé D
    J Investig Allergol Clin Immunol; 2017; 27(5):326-327. PubMed ID: 29057743
    [No Abstract]   [Full Text] [Related]  

  • 13. Urticaria control test might misevaluate disease control in particular patients treated with omalizumab.
    Türk M; Yılmaz İ
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):342-343. PubMed ID: 30529015
    [No Abstract]   [Full Text] [Related]  

  • 14. Solar urticaria treated with omalizumab.
    Schaffenburg WC; Guerrero KT; Marks SN
    Cutis; 2019 Jul; 104(1):E4-E5. PubMed ID: 31487346
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.
    Metz M; Schütz A; Weller K; Gorczyza M; Zimmer S; Staubach P; Merk HF; Maurer M
    J Allergy Clin Immunol; 2017 Sep; 140(3):864-867.e5. PubMed ID: 28389393
    [No Abstract]   [Full Text] [Related]  

  • 16. Response of omalizumab in normocomplementemic urticarial vasculitis.
    Chen YD; Krause K; Tu P; Zhao ZT; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2114-2117.e2. PubMed ID: 32145404
    [No Abstract]   [Full Text] [Related]  

  • 17. Home self-administration of omalizumab for chronic spontaneous urticaria.
    Denman S; Ford K; Toolan J; Mistry A; Corps C; Wood P; Savic S
    Br J Dermatol; 2016 Dec; 175(6):1405-1407. PubMed ID: 27639259
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic Idiopathic Urticaria.
    Wu EY; Saini SS
    J Allergy Clin Immunol Pract; 2015; 3(6):1003-4; quiz 105. PubMed ID: 26553623
    [No Abstract]   [Full Text] [Related]  

  • 19. Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria.
    Jesenak M; Ciljakova M; Janickova M; Banovcin P
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):144-146. PubMed ID: 31017115
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-life treatment of cholinergic urticaria with omalizumab.
    Altrichter S; Chuamanochan M; Knoth H; Asady A; Ohanyan T; Metz M; Maurer M
    J Allergy Clin Immunol; 2019 Feb; 143(2):788-791.e8. PubMed ID: 30312709
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.